If you or someone you care for has been prescribed Wegovy, one of the first questions is usually whether Medicare will help pay for it. The honest answer is that it depends entirely on why it was prescribed — and the difference matters more here than with almost any other drug.
What Wegovy treats
Wegovy (semaglutide) is a once-weekly injection with two FDA-approved uses:
- Chronic weight management.
- Reducing the risk of cardiovascular events — heart attack and stroke — in adults who have established cardiovascular disease and are overweight or obese.
That second use is the key to coverage, and we’ll come back to it. It’s also worth knowing that the same medicine, semaglutide, is sold under a different name — Ozempic — for type 2 diabetes. Same active ingredient, different brand and different approved uses.
Brand vs. generic
Wegovy is a brand-name drug, and there is no generic version available. Because it’s a brand-name injectable with no lower-cost generic to fall back on, plans tend to place it on a brand or specialty tier when they cover it at all. Generics, when they exist, usually sit on lower tiers — but that option isn’t on the table here yet.
How Medicare covers it
This is the heart of the matter, so let me be precise.
By law, Medicare cannot cover any drug used for weight loss. That’s a long-standing federal rule, and it applies no matter how well the drug works. So if Wegovy is prescribed for weight loss alone, Medicare will not cover it.
However, Medicare Part D plans can cover Wegovy when it’s prescribed for the cardiovascular-risk-reduction use — that’s a separate, FDA-approved, medically-accepted indication, not a weight-loss prescription. So your coverage hinges on the documented reason for the prescription and the diagnosis behind it.
When Wegovy is covered, it runs through Part D — either a standalone drug plan added to Original Medicare, or the drug coverage built into a Medicare Advantage plan. As with all Part D drugs, whether a specific plan lists it, and on what tier, varies by plan and changes each year.
Coverage rules to expect
Because coverage depends so heavily on the why, plans lean on utilization management to confirm it. Expect to see:
- Prior authorization. This is almost a given for Wegovy. Your doctor submits documentation to confirm the qualifying cardiovascular-risk-reduction indication — including the established cardiovascular disease and weight criteria — before the plan will cover it.
- Step therapy. Some plans may ask you to try a preferred alternative first before they’ll cover this one.
- Quantity limits. Plans often cover only a set amount per fill or period without an approved exception.
None of these are dead ends — they’re steps your doctor’s office handles routinely. You can read more about prior authorization and step therapy if you’d like to understand the process.
Coverage exceptions and appeals
If your plan denies Wegovy, you and your prescriber have the right to request a coverage exception and to appeal. Your doctor can submit a statement explaining why the drug is medically necessary for your situation. If the first decision doesn’t go your way, there are formal appeal levels beyond it — so a denial isn’t necessarily the end of the road.
Alternatives to discuss with your doctor
Because Wegovy serves two very different goals, the right alternative depends on what you and your doctor are treating. I’m an insurance agent, not a physician, so think of these as conversations to have with your prescriber — not recommendations:
- If the goal is managing type 2 diabetes, there are several covered drug classes worth discussing, and our Ozempic article walks through that side.
- If the goal is reducing cardiovascular risk, your doctor can talk through which therapies fit your heart history.
- Another GLP-1-type option in this space is Zepbound — you can see how Medicare treats it in our Zepbound article.
Please don’t start, stop, or change any medication on your own. Your doctor decides what’s right for your health; my job is just to help you understand the coverage.
A note on drug-price negotiation
One piece of forward-looking news: semaglutide is in the second group of drugs selected for Medicare price negotiation, with a negotiated price effective January 1, 2027. That doesn’t change today’s coverage rules, but it’s worth keeping on your radar.
Questions to ask your doctor
- Is my Wegovy prescription for cardiovascular risk reduction, and is that diagnosis documented?
- Do I meet the established-cardiovascular-disease and weight criteria for that use?
- What information will you need to submit for prior authorization?
- If my plan denies it, will you help request an exception or appeal?
Check your plan, then let’s talk
Coverage for Wegovy really does come down to the documented reason behind the prescription and the fine print of your specific plan. The most useful first step is to look it up on your own plan’s covered-drug list. Our Formulary Lookup shows how a drug is treated, the Drug Cost Calculator helps you estimate what you’d pay across the year, and the Medicare Cost Estimator gives you the bigger picture.
If you’d like a hand sorting out where your plan stands — no pressure — you can reach out anytime and we’ll look at your formulary and costs together.
Medical & coverage disclaimer: This article is general education — not medical advice or a guarantee of coverage. Whether a specific drug is covered, and what you’ll pay, depends on your individual Part D or Medicare Advantage plan, its formulary, and the plan year, and can change. Always confirm with your plan or a licensed agent, and talk to your doctor about your treatment.